In the previously published RCT study (31), the researchers found that patients with COVID-19 receiving lopinavir-ritonavir along with interferon beta-1b and ribavirin had a significantly lower level of IL-6 at days 2, 6, and 8 in comparison with patients who only received lopinavir and ritonavir. The gene discussed is IL6; the disease is COVID-19.